| Literature DB >> 36155559 |
Alem Alemayehu1,2,3, Abebaw Kebede1,4, Sebsib Neway2, Efrem Tesfaye4, Betselot Zerihun4, Melak Getu4, Beyene Petros1.
Abstract
Laboratory identification of nontuberculous mycobacteria (NTM) species is not regularly performed while, they have a public health importance with a prevalence of more than 5% among pulmonary tuberculosis (PTB) patients in Ethiopia. Hence, this study aimed to identify the NTM species and their clinical significance among PTB patients. A retrospective study was conducted at the Ethiopian Public Health Institution's (EPHI's) national TB referral laboratory. Stored NTM isolates were genotyped using GenoType Mycobacterium CM/AS kit (Hain Life science, Germany). Data pertinent to the study was extracted from the EPHI's database and patients' medical records. Between January 2 & December 28 of 2017, a total of 3,834 samples were processed from 698 TB patients of whom 50% were female. Among 3,317 samples with mycobacterial culture results 7.3% were NTM and majority of them were identified from smear negative TB patients. M. simiae was the /predominant NTM among the genotyped isolates. All the studied NTM species were not clinically important however, considering the similarity of clinical and radiologic findings between NTM and MTBC infected patients, integrating NTM species identification in the routine TB laboratory diagnosis may augment clinicians' decision particularly in DR-TB patients. Additional similar prospective study with a larger sample size is recommended. Moreover, urgent improvements on patients' record keeping practice are required in the studied hospitals.Entities:
Mesh:
Year: 2022 PMID: 36155559 PMCID: PMC9512186 DOI: 10.1371/journal.pone.0275159
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Flow chart of PTB patient and sample identification with NTM and MTBC.
Frequency distribution NTM isolation among PTB patients at EPHI Ethiopia.
| Study variables | Frequency | Percent (%) | |
|---|---|---|---|
|
| Women | 26 | 51 |
| Men | 25 | 49 | |
| NR | 2 | 3.9 | |
| Total | 51 | 100 | |
|
| </ = 19 | 10 | 19.6 |
| 20–29 | 15 | 29.4 | |
| 30–39 | 13 | 25.5 | |
| 40–49 | 5 | 9.8 | |
| 50–59 | 3 | 5.9 | |
| >/ = 60 | 3 | 5.9 | |
| Total | 51 | 100 | |
|
| Non-reactive | 15 | 29.4 |
| Reactive | 8 | 15.7 | |
| NR | 28 | 54.9 | |
| Total | 51 | 100 | |
|
| New | 14 | 27.5 |
| Relapse | 12 | 23.5 | |
| Default | 1 | 2 | |
| Treatment failure | 7 | 13.7 | |
| NR | 17 | 33.3 | |
| Total | 51 | 100 | |
|
| Diagnosis | 6 | 11.8 |
| Follow up | 39 | 76.5 | |
| NR | 6 | 11.8 | |
| Total | 51 | 100 | |
|
| Negative | 42 | 82.4 |
| Positive | 9 | 17.6 | |
| Total | 51 | 100 | |
*Includes all patients referred for MTBC culture after starting anti TB drug treatment irrespective of the follow up month, NR: Not recorded.
Fig 2NTM species isolated from PTB patients at EPHI, Ethiopia.
Patients clinical and microbiologic characteristics according to the AST diagnostic guide line.
| Patient Ser N | NTM species | AFB | TB classification | Treatment line | Underlying comorbidities | Clinical (All required) | Microbiologic | Remark | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical: Pulmonary symptoms | Radiography: nodular or cavitary opacities or multifocal bronchiectasis with multiple small nodules | Appropriate exclusion of other diagnoses | Positive culture results from at least two separate expectorated sputum samples | Positive culture result from at least one bronchial wash or lavage | Transbronchial or other lung biopsy with mycobacterial histopathologic features and positive culture for NTM or biopsy showing mycobacterial histopathologic features | |||||||
|
|
| Negative | New case | 2nd line | NR | Cough, Chest pain, weight loss | NR | Improved with anti- TB drug treatment | Only from single sputum | ND | ND |
|
|
|
| Negative | Treatment failure | 1st&2nd line | NR | NR | cured with anti-TB drug treatment | Only from single sputum | ND | ND |
| |
|
|
| Negative | New case | 2nd line | DMII | Cough, weight loss | NR | Improved with anti- TB drug treatment | Only from single sputum | ND | ND |
|
|
|
| Negative | Treatment failure | 1st&2nd line | NR | Cough, chest pain | NR | NR | Only from single sputum | ND | ND |
|
|
|
| Negative | Treatment failure | 2nd line | NR | Cough, chest pain, fever, weight loss, fatigue | NR | Improved with anti -TB drug treatment | Only from single sputum | ND | ND |
|
|
|
| Positive | Relapse | NR | NR | Cough, chest pain, fatigue | NR | NR | Only from single sputum | ND | ND |
|
NR; Not recorded, CNI; Clinically not important based on the stated criteria of ATS.